![](/img/cover-not-exists.png)
1472PAfatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study
de Marinis, F, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Passaro, A, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, NovellVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz259.015
Date:
October, 2019
File:
PDF, 88 KB
2019